Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Coffey

Showing results (461-470 of 512) with videos related to

Pageof 52
Sort By:
JAMA Neurology|August 28, 2013
Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson diseaseJu-Hee Kang, David J Irwin, Alice S Chen-Plotkin, et al.
The Lancet. Neurology|December 21, 2010
Very early hypothermia induction in patients with severe brain injury (the National Acute Brain Injury Study: Hypothermia II): a randomised trialGuy L Clifton, Alex Valadka, David Zygun, et al.
Neurology|August 22, 2022
Association of Olfactory Performance With Motor Decline and Age at Onset in People With Parkinson Disease and the <i>LRRK2</i> G2019S VariantRachel Saunders-Pullman, Roberto Angel Ortega, Cuiling Wang, et al.
Annals of Neurology|June 17, 2020
Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's DiseaseDavid J Irwin, Janel Fedler, Christopher S Coffey, et al.
Neurology|August 5, 2020
In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson diseaseLana M Chahine, Thomas G Beach, Michael C Brumm, et al.
Scientific Reports|October 28, 2018
Publisher Correction: 3D Shape Modeling for Cell Nuclear Morphological Analysis and ClassificationAlexandr A Kalinin, Ari Allyn-Feuer, Alex Ade, et al.
Scientific Reports|September 14, 2018
3D Shape Modeling for Cell Nuclear Morphological Analysis and ClassificationAlexandr A Kalinin, Ari Allyn-Feuer, Alex Ade, et al.
Movement Disorders Clinical Practice|June 19, 2023
Impact of the Dopamine System on Long-Term Cognitive Impairment in Parkinson Disease: An Exploratory StudyDaniel Weintraub, Marina Picillo, Hyunkeun Ryan Cho, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 14, 2021
Safety and efficacy of N-acetylmannosamine (ManNAc) in patients with GNE myopathy: an open-label phase 2 studyNuria Carrillo, May C Malicdan, Petcharat Leoyklang, et al.
Annals of Neurology|May 14, 2026
Identification and Enrollment of Individuals Prior to Parkinson's Disease Diagnosis: Biomarker-Driven Adaptive Eligibility and Enrollment into the Parkinson's Progression Markers InitiativeEthan G Brown, Lana M Chahine, Roseanne D Dobkin, et al.
Pageof 52

Showing results (461-470 of 512) with videos related to

Sort By:
Pageof 52
JAMA Neurology|August 28, 2013
Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson diseaseJu-Hee Kang, David J Irwin, Alice S Chen-Plotkin, et al.
The Lancet. Neurology|December 21, 2010
Very early hypothermia induction in patients with severe brain injury (the National Acute Brain Injury Study: Hypothermia II): a randomised trialGuy L Clifton, Alex Valadka, David Zygun, et al.
Neurology|August 22, 2022
Association of Olfactory Performance With Motor Decline and Age at Onset in People With Parkinson Disease and the <i>LRRK2</i> G2019S VariantRachel Saunders-Pullman, Roberto Angel Ortega, Cuiling Wang, et al.
Annals of Neurology|June 17, 2020
Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's DiseaseDavid J Irwin, Janel Fedler, Christopher S Coffey, et al.
Neurology|August 5, 2020
In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson diseaseLana M Chahine, Thomas G Beach, Michael C Brumm, et al.
Scientific Reports|October 28, 2018
Publisher Correction: 3D Shape Modeling for Cell Nuclear Morphological Analysis and ClassificationAlexandr A Kalinin, Ari Allyn-Feuer, Alex Ade, et al.
Scientific Reports|September 14, 2018
3D Shape Modeling for Cell Nuclear Morphological Analysis and ClassificationAlexandr A Kalinin, Ari Allyn-Feuer, Alex Ade, et al.
Movement Disorders Clinical Practice|June 19, 2023
Impact of the Dopamine System on Long-Term Cognitive Impairment in Parkinson Disease: An Exploratory StudyDaniel Weintraub, Marina Picillo, Hyunkeun Ryan Cho, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 14, 2021
Safety and efficacy of N-acetylmannosamine (ManNAc) in patients with GNE myopathy: an open-label phase 2 studyNuria Carrillo, May C Malicdan, Petcharat Leoyklang, et al.
Annals of Neurology|May 14, 2026
Identification and Enrollment of Individuals Prior to Parkinson's Disease Diagnosis: Biomarker-Driven Adaptive Eligibility and Enrollment into the Parkinson's Progression Markers InitiativeEthan G Brown, Lana M Chahine, Roseanne D Dobkin, et al.
Pageof 52